PLURI INC (PLUR)
US72942G2030 - Common Stock
PLUR Stock Earnings: Pluri Reported Results for Q4 2023
Pluri just reported results for the fourth quarter of 2023.
PLUR Stock Earnings: Pluri Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pluri (NASDAQ:PLUR) just reported results for the fourth quarter of 2023.Pluri ...
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri’s business verticals leverage Company’s world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring...
Pluri Inc. Announces 1-for-8 Reverse Share Split
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee...
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF)...
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical...
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering...
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
Abony: “Pluri’s cell expansion technology has extraordinary potential across a range of industries.”...
Pluri stock soars on $4.2M contract from U.S. National Institutes of Health (NASDAQ:PLUR)
Pluri (PLUR) said on Tuesday that it had signed a three-year $4.2M contract with the U.S
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear...
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional...
Pluri prices private placement (NASDAQ:PLUR)
Pluri (PLUR) on Thursday after the bell announced it signed securities purchase agreements with domestic and non-U.S
Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company,...
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheetLeading European manufacturer of active...
Pluri CEO Issues Shareholder Update
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem...
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based...